AstraZeneca PLC and its China-based partner Chi-Med (Hutchison China MediTech Ltd.) have highlighted preliminary clinical evidence that the addition of the investigational agent, savolitinib, to other anticancer therapies may be of clinical benefit in certain non-small cell lung cancer (NSCLC) patients whose tumors have become resistant to therapy.
Patients with epidermal growth factor receptor (EGFR) mutation-positive advanced NSCLC can experience disease progression through a process called MET amplification,...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)